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The use of human pluripotent stem cells in basic and translational cardiac research requires efficient differentiation protocols
towards cardiomyocytes. In vitro differentiation yields heterogeneous populations of ventricular-, atrial-, and nodal-like cells
hindering their potential applications in regenerative therapies. We described the effect of the growth factor Activin A during early
human embryonic stem cell fate determination in cardiac differentiation. Addition of high levels of ActivinAduring embryoid body
cardiac differentiation augmented the generation of endoderm derivatives, which in turn promoted cardiomyocyte differentiation.
Moreover, a dose-dependent increase in the coreceptor expression of the TGF-𝛽 superfamily member CRIPTO-1 was observed in
response to Activin A. We hypothesized that interactions between cells derived from meso- and endodermal lineages in embryoid
bodies contributed to improved cell maturation in early stages of cardiac differentiation, improving the beating frequency and
the percentage of contracting embryoid bodies. Activin A did not seem to affect the properties of cardiomyocytes at later stages
of differentiation, measuring action potentials, and intracellular Ca2+ dynamics. These findings are relevant for improving our
understanding on human heart development, and the proposed protocol could be further explored to obtain cardiomyocytes with
functional phenotypes, similar to those observed in adult cardiac myocytes.
1. Introduction
The generation of functional cardiomyocytes (CMs) differ-
entiated from pluripotent stem cell (PSC) lines offers an
extraordinary platform to develop novel cell-based thera-
pies, to establish predictive drug toxicology tests, to model
human diseases in vitro, and to study human embryonic
development [1]. Strategies to efficiently direct differentiation
of human embryonic stem cell (ESC) and induced pluripotent
stem cell (iPSC) lines towards cardiovascular lineages are of
particular interest due to the high morbidity and mortality of
cardiovascular diseases in theWestern world. So far, themost
successful in vitro differentiation approaches are those that
recapitulate the regulatory pathways of embryonic cardiac
development (reviewed in [2, 3]).
PSC differentiation to CMs has made considerable
progress in the past decade. One of the first directed differen-
tiation protocols described involves the coculture of human
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ESCs with mouse visceral endoderm-like cells (END-2) [4].
Currently, two basic methods for cardiac differentiation of
humanPSC lines are in use: differentiation of cultured human
PSCs as amonolayer and as embryoid bodies (EBs) (reviewed
in [2, 3]).
Studies, using different model organisms, have demon-
strated that the morphogenic Activin A (ActA)/NODAL,
bone morphogenetic protein (BMP), and Wnt signaling
pathways played pivotal roles in the establishment of a
cardiovascular cell fate [5–16]. Recently published reports
have shown that BMP4 and basic fibroblast growth factor
(bFGF) signaling modulated ActA-induced mesendoderm
differentiation in mouse [17–19] and human ESC cultures
[20]. Moreover, the combinatorial effects of BMP4 and ActA
induced cardiovascular development in serum-free human
ESCs [21, 22]. Kattman et al. have reported that individual
mouse and human PSC lines required optimization for the
proper balance of the BMP4 and ActA signaling cascade
to achieve efficient cardiac differentiation [23]. However,
these studies did not define a stage-specific role for these
morphogens nor the influence of different levels of signaling
on the differentiation.
BMPs and ActA are members of the transforming growth
factor beta (TGF-𝛽) superfamily and control a wide range of
fundamental cellular processes, including tissue patterning
during embryogenesis and cell proliferation and differen-
tiation. These TGF-𝛽 ligands exert their biological effects
by binding and assembling two types of transmembrane
receptors (type I and type II) with intrinsic serine/threonine
kinase activities [24, 25]. ActA binds to type II receptor,
ACVR2A or ACVR2B, leading to oligomerization, which
recruits and phosphorylates the activin type I receptor-like
kinase 4 (ALK4, or also known as ACVR1B) (reviewed in
[26]). ActA and NODAL utilize the same signaling receptors,
although their mechanism of ligand-mediated interaction
with their receptor is different. NODAL lacks intrinsic affinity
for ACVR2A/2B and ALK4 and requires CRIPTO-1, also
known as teratocarcinoma-derived growth factor-1 (TDGF1),
which belongs to the epidermal growth factor-Cripto-FRL1-
Cryptic (EGF-CFC) family, and it has a pivotal role during
embryogenesis and tumorigenesis [27]. Studies have shown
that NODAL assembled type II and type I receptors only
when CRIPTO-1 was present [28, 29]. During mouse embry-
onic development, Cripto-1 was expressed in the inner cell
mass of blastocysts at day 4 and in the primitive streak
at day 6.5 [30]. Xu et al. have demonstrated that mouse
ESCs lacking Cripto-1 expression lost the ability to form
beating CMs in vitro [31]. More interestingly, mouse Cripto-1
deficient embryos died at around day 6.5 due to mesoderm
formation defects [32]. Minchiotti et al. have documented
that Cripto-1 signaling was crucial for priming differentiation
of mouse ESCs into functional CMs [33, 34]. Recently,
Fiorenzano et al. provided evidence that CRIPTO-1 was a
major determinant of mouse epiblast stem cell (EpiSC) and
human ESC pluripotency, suggesting an earlier function of
CRIPTO-1 than previously recognized in the very first lineage
decision made by the early embryo [35].
In this study, we investigated the role of the ActA
signaling pathway during CM differentiation from human
ESCs. The expression of the mesoderm marker BRACH
and the endoderm-associated markers SOX17 and HNF4𝛼
confirmed ActA addition as a robust inducer of mesendo-
derm formation. We showed that high doses of ActA (50
and 100 ng/mL), added during the initial stage of cardiac
differentiation, improved cell maturation in the early stages
of differentiation. Specifically, ActA increased the percentage
of contracting EBs and the beating frequency of these EBs.
CRIPTO-1 acting in the early time window of ESC differen-
tiation might be responsible for priming the CM cell fate.
Finally, we demonstrated that early commitment by ActA
appeared to improve cardiac cell type specification and that
ActA-mediated differentiation of human ESC-derived CMs
(ESC-CMs) allowed the production of CMs with atrial- and
ventricular-like action potentials (APs) and Ca2+ dynamics
supporting advanced maturation of the cells. In conclusion,
human ESC-derived EBs treated with high ActA concen-
trations during the first two days of cardiac differentiation
responded by increasing numbers of definitive endodermal
cells, which in turn promoted CM differentiation and early
cell maturation in the early stages of differentiation.
2. Material and Methods
2.1. Human Embryonic Stem Cell Culture. Human ESC lines,
H1 (WA01) and H9 (WA09, both from WiCell Research
Institute), were used between passages 43 and 63 and had a
normal karyotype, checked by WiCell Cytogenetic Services.
To maintain ESCs in culture, human ESCs were cultured
on a feeder layer of irradiated mouse embryonic fibroblasts
(MEFs, GlobalStem) under hypoxic conditions. Undifferen-
tiated cells on MEFs were cultured in normal maintenance
medium for human ESC lines: knockout DMEM/F12 and
20% knockout serum replacement (KSR) supplemented with
2mM L-glutamine, 1% nonessential amino acids (NEAA),
0.1mM𝛽-mercaptoethanol, 0.5%Pen/Strep (all fromThermo
Fisher Scientific), and 10 ng/mL bFGF (PeproTech). Prior
to differentiation, the human ESCs were feeder depleted by
culturing on a thin growth factor reduced (GFR) Matrigel
layer (BD Biosciences) for at least three passages. Feeder-
free cultures were in complete serum-free mTeSR medium
(STEMCELL Technologies), consisting of basal medium and
5x supplement with recombinant human bFGF and TGF-𝛽
and maintained under normoxia. NKX2.5eGFP/w human ESC
line was kindly provided by Elliott et al. [36].
2.2.HumanEmbryonic StemCell CardiacDifferentiation. The
EB-based protocol, previously described by Burridge et al.
[37–39], was used to differentiate the human ESC lines (H1
and H9) into functional CMs (Figure 1(a)).
One day before cardiac differentiation induction, human
ESCs, cultured feeder-free on Matrigel, were dissociated into
single cells with TrypLE (Thermo Fisher Scientific) at 37∘C
for 2 minutes and seeded in Matrigel-coated cell culture
flasks at 1.0–1.5 × 105 cells/cm2 in mTeSR medium supple-
mented with 10 𝜇M Rho-associated protein kinase (ROCK)
inhibitor (Y-27632; VWR). At day 0 of differentiation, cells
reached 80–90% of confluency and were dissociated with
TrypLE and plated in V-bottom uncoated 96-well multiwell
Stem Cells International 3
RPMI + growth factors
RPMI + 20% FBS
RPMI
Split
Days of differentiation Days of differentiation
BRACH
2 4 7 10 13 16 19
ESC H9
ESC H1
ESC H9
ESC H1
ESC H9
ESC H1
Days of differentiation
Days of differentiation Days of differentiation Days of differentiation
Days of differentiation Days of differentiation Days of differentiation
−20
−15
−10
−5
0
5
Δ
C t
−20
−15
−10
−5
0
5
Δ
C t
−20
−15
−10
−5
0
5
Δ
C t
−20
−15
−10
−5
0
5
Δ
C t
−1
2 4 7 10 13 16 19
OCT4
2 4 7 10 13 16 19
NKX2.5
2 4 7 10 13 16 19
TNNT2
2 4 7 10 13 16 19
NANOG
2 4 7 10 13 16 19
GATA4
2 4 7 10 13 16 19
TNNI3
−20
−15
−10
−5
0
5
Δ
C t
−20
−15
−10
−5
0
5
Δ
C t
2 4 7 10 13 16 19
cMyHC
2 4 7 10 13 16 19
HCN4
hPSCs
(a)
(c)
(d)
(b)
Mesoderm Cardiacmesoderm
Cardiac
progenitors CMs
V-Bottom Plate F-Bottom Plate
0 1 2 3 4 5 6 8 9 10 11 12 13 14 15 167
BMP4
bFGF IWR-1
cMyHC/CX43/HOECHST
0
76.20%
23.80%
Undifferentiated
cells
cMyHC+
cMyHC−
10
4
10
5
10
3
cMyHC
0
100
200
300
C
ou
nt
−15
−10
−5
0
5
Δ
C t
−15
−10
−5
0
5
Δ
C t
−15
−10
−5
0
5
Δ
C t
Figure 1: Continued.
4 Stem Cells International
(e)
(f)
(g)
(h)
ESCs ESC-CMs
cMyHC
(223 kDa)
GAPDH
(36kDa)
Control Isoprenaline
∗∗∗
0
25
50
75
100
Be
at
in
g 
fre
qu
en
cy
 (#
/m
in
)
Time
F
/F
0
[C
a2
+
]
10 s
I N
a
1
nA
50ms
+10mV
−120mV −100mV
it
ra
ns
ie
nt
s
Figure 1: Characterization of the embryoid body- (EB-) based cardiac differentiation protocol. Characterization was performed on human
embryonic stem cell-derived cardiomyocytes (ESC-CMs) without the addition of Activin A (ActA) during the early stage of differentiation
(control condition). (a) Schematic representation of the EB-based cardiac differentiation protocol. (b) Expression profiles for pluripotency
(OCT4 and NANOG), mesodermal (BRACH), cardiac progenitor (NKX2.5 and GATA4), and late-stage CM (cMyHC, TNNT2, TNNI3, and
HCN4) markers, monitored during 19 days of differentiation. (c) IF analyses of dissociated EBs at day 20 of differentiation, showing areas of
connected CMs (cMyHC; red) expressing connexin 43 (CX43; green). Nuclei were stained with Hoechst (blue). (d) Flow cytometry analyses
of cMyHC+ CMs at day 20 of differentiation. Representative example of three independent experiments. (e)Western blot analyses quantifying
the cMyHCprotein levels of undifferentiatedESCs andCMs after 20 days of differentiation, normalized byGAPDH. (f)𝛽-Adrenergic response
of CMs to isoprenaline (1𝜇M; isoproterenol), triggered at day 20 of differentiation. (g) Time course of intracellular Ca2+ handling at day 20
of differentiation, using the Ca2+-sensitive fluorescent indicator Fluo-4 (2.5𝜇M), monitored by confocal microscopy. (h) Whole-cell Na+
recording, accessed by applying 500ms voltage pulses to potentials between −120 and +10mV in 5mV increments from a holding potential
of −100mV at 0.5Hz. RT-QPCR data are represented as ΔC𝑡, normalized for the housekeeping genes GAPDH, HPRT, and RPL13a. Data are
representative of three independent experiments and values are expressed as mean ± standard error of the mean (SEM). Significant difference
is versus control and indicated as 𝑃 < 0.001: ∗∗∗. Scale bar = 100 𝜇m.
plates at a density of 5500 cells per well under hypoxia
in a mesoderm induction medium containing RPMI 1640
(Thermo Fisher Scientific) with 1% chemically defined lipid
concentrate (Thermo Fisher Scientific), 10𝜇g/mL recombi-
nant human insulin (Sigma-Aldrich), 450𝜇M 1-Thioglycerol
(Sigma-Aldrich), 2mg/mL polyvinyl alcohol (PVA; Sigma-
Aldrich), 0.1% Pen/Strep (Thermo Fisher Scientific), 1 𝜇M
Y-27632, and the growth factors BMP4 (25 ng/mL), bFGF
(5 ng/mL), and ActA (ranging from 0 to 100 ng/mL; all
from PeproTech). PVA enhances EB formation and sub-
sequently cardiac specification. At day 2, medium was
changedwithRPMI 1640 containing 20% foetal bovine serum
(FBS; Thermo Fisher Scientific), 50 𝜇g/mL L-ascorbic acid
2-phosphate (Sigma-Aldrich) [40], 450 𝜇M 1-Thioglycerol,
and 0.1% Pen/Strep and incubated for 48 h under normoxic
conditions. At day 4, EBs were transferred to tissue culture-
treated 96-well plates and incubated for 72 h with RPMI 1640
supplemented with 4 𝜇Mof theWnt inhibitor IWR-1 (Sigma-
Aldrich). From day 10 onwards, medium without IWR-1 was
used. In CRIPTO-1 interfering experiments, 5 𝜇M of the
CFC1/CRIPTO-1 blocking peptide (CRIPTO-1 BP; GeneTex)
was added to differentiating human ESCs during the first step
of the differentiation protocol (from days 0 to 2). To validate
the blocking efficiency of the CFC1/CRIPTO-1 BP in vitro,
cells were treated with a CRIPTO-1 antibody (Thermo Fisher
Scientific, PA1-16534; 10 𝜇M).
2.3. Quantitative Real-Time PCR. Total RNA was extracted
using the PureLink RNAMini Kit (Thermo Fisher Scientific)
and treatedwith theDNA-Free Kit (ThermoFisher Scientific)
to assure highly pure RNA. 0.5 𝜇g RNA was reverse tran-
scribed into cDNAwith Superscript III Reverse Transcriptase
First-Strand Synthesis SuperMix (Thermo Fisher Scientific).
Quantitative real-time PCR was performed with the Plat-
inum SYBR Green qPCR SuperMix-UDG (Thermo Fisher
Scientific). The oligonucleotide primer sequences are listed
in Supporting Information Table S1 (all from IDT). A 10-fold
dilution series ranging from 10−3 to 10−8 of 50 ng/𝜇L human
genomic DNA was used to evaluate the primer efficiency.
Relative expression values were obtained by normalizing C𝑡
values of the tested genes to C𝑡 values of the housekeeping
genes GAPDH, HPRT, and RPL13a.
2.4. Immunofluorescence Staining. EBs at day 7 in the differ-
entiation process were stained for CM and early endodermal
progenitor cell characterization. Cells were fixed with 4%
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paraformaldehyde (PFA; Polysciences) for 10 minutes at 4∘C,
permeabilized in PBS (Thermo Fisher Scientific) containing
0.2% Triton X-100 (Sigma-Aldrich) and 1% bovine serum
albumin (BSA; Sigma-Aldrich) for 30 minutes, and blocked
in 10% donkey serum (Sigma-Aldrich) for 30 minutes.
Cells were incubated overnight at 4∘C with the following
primary antibodies: cardiac myosin heavy chain (cMyHC;
Abcam BA-G5; 10 𝜇g/mL), connexin 43 (CX43; Santa Cruz
H-150; 0.67 𝜇g/mL), and hepatocyte nuclear factor 4 alpha
(HNF4𝛼; Abcam, K9218; 5 𝜇g/mL), followed by the appropri-
ate Alexa Fluor 488- and 594-conjugated secondary antibody
(Thermo Fisher Scientific; 4 𝜇g/mL). Nuclei were stained
with Hoechst (33342, Thermo Fisher Scientific; 1 : 3000)
for 1 minute. Analyses were assessed using an Eclipse Ti
Microscope and NIS-Elements AR 4.11 Software (both from
Nikon).
2.5. Western Blot. Cells were lysed in RIPA buffer sup-
plemented with 10mM sodium fluoride, 0.5mM sodium
orthovanadate, 1 : 100 protease inhibitor cocktail, and 1mM
Phenylmethylsulfonyl Fluoride (PMSF). Equal amounts of
protein (40𝜇g)were heat-denatured in sample-loading buffer
(50mM Tris-HCl, pH 6.8, 100mM DTT, 2% SDS, 0.1%
bromophenol blue, and 10% glycerol), resolved by SDS-
polyacrylamide gel electrophoresis, and then transferred to
nitrocellulose membranes.The filters were blocked with Tris-
buffered saline (TBS) containing 0.05%Tween and 5% nonfat
dry milk and then incubated overnight at 4∘C with the
primary antibody cMyHC (Abcam, BA-G5; 2 𝜇g/mL) and
normalized for GAPDH (Sigma-Aldrich G9545; 1𝜇g/mL).
Secondary horseradish peroxidase- (HRP-) conjugated anti-
body was diluted 1 : 5000 in TBS-Tween and 2.5% nonfat dry
milk. After incubation with SuperSignal Dura Chemilumi-
nescence substrate, the polypeptide bands were detected with
GelDoc chemiluminescence detection system. Quantitation
was performed on gels loaded and blotted in parallel and rel-
ative densitometry was obtained by normalizing the protein
band versus background and housekeeping protein using the
QuantityOne Software.
2.6. Flow Cytometry Analysis. Undifferentiated ESCs or EBs
were harvested and dissociated with Collagenase IV for 20
minutes and StemPro Accutase Cell Dissociation Reagent
(both fromThermo Fisher Scientific) for 3 minute at 37∘C. To
analyze the presence of CRIPTO-1 on HNF4𝛼+ endodermal
cells, EBs in early cardiac differentiation were dissociated,
fixed with PFA for 10 minutes at 37∘C, and permeabilized
in ice-cold 90% methanol (Sigma-Aldrich) for 30 minutes
on ice. Samples were stained for 1 hour at 37∘C with the
following antibodies: CRIPTO-1 (Thermo Fisher Scientific
PA1-16534; 1 𝜇g/mL) and HNF4𝛼 (Abcam K9218; 1 𝜇g/mL),
followed by the appropriate Alexa Fluor 488- and 647-
conjugated secondary antibody (Thermo Fisher Scientific;
1 𝜇g/mL) for 30minutes at 37∘C. To determine the percentage
of cMyHC+ CMs after cardiac differentiation without the
addition of ActA, PFA fixed and methanol permeabilized
EBs were stained for 1 hour at 37∘C with the primary
antibody cMyHC (Abcam, 3–48; 1.67𝜇g/mL), followed by the
appropriate Alexa Fluor 647-conjugated secondary antibody
(Thermo Fisher Scientific; 1 𝜇g/mL) for 30 minutes at 37∘C.
To evaluate a possible ActA additional proliferative effect
on EBs in early cardiac differentiation, Ki-67 and 7-AAD
(7-Aminoactinomycin D) staining assay were performed.
PFA fixed and methanol permeabilized EBs were stained
for 20 minutes at RT with the primary antibody Ki-67 (BD
Pharmingen, B56; 1 𝜇g/mL), followed by the Alexa Fluor 647-
conjugated secondary antibody (Thermo Fisher Scientific;
1 𝜇g/mL) for 20 minutes at RT. The 7-AAD staining (eBio-
science; 1 : 25) was performed with unfixed cells, incubated
for 5 minutes at RT. Hanks’ Balanced Salt Solution (HBSS;
Thermo Fisher Scientific) with CaCl2 and MgCl2 supple-
mented with 2% FBS, 10mMHEPES, and 10mMNaN3 (both
from Sigma-Aldrich; pH 7.2) was used as staining buffer.
Cells were analyzed and quantified by flow cytometry (BD
FACSCanto I or II with HTS; BD Biosciences) and FlowJo
Software (FlowJo LLC).
2.7. Patch Clamp Electrophysiology and Ca2+ Measurements.
Single cells were seeded on Matrigel-coated coverslips for
whole-cell patch clamp and Ca2+ recordings. Cells were
perfused with a solution containing the following (in mM):
137 NaCl, 5.4 KCl, 1.8 CaCl2, 0.5 MgCl2, 10 glucose, and 10
Na-HEPES; pH was adjusted to 7.4 with NaOH. The patch
clamp pipettes were filled with a solution containing the
following (in mM): 120K-Asp, 20 KCl, 10 HEPES, 5 Mg-ATP,
10 NaCl, and 0.05 K5Fluo-4; pH was adjusted to 7.2 with
KOH.
APs weremeasured during whole-cell current clampwith
an EPC-9 amplifier (HEKA Elektronik) at a sampling rate
of 10 kHz. Patch electrode resistances were between 2.5 and
3MΩwhen filledwith intracellular solution. Capacitance and
access resistance were monitored continuously. Experiments
were performed at 37∘C. APs were recorded after a 5ms pulse
of 300 pA, at a 1Hz frequency. Signals were filtered with
2.9 kHz and 10KHz Bessel filters. Data were analyzed with
Clampfit.
Simultaneously with the patch clamp recordings, 2D
images acquisition of the Fluo-4 signal was recorded using
a confocal microscope (Nikon A1R, resonant mode, 40x 1.3
NA oil immersion objective) at a scan speed of 1 image each
110ms (average of 4 images).Datawere analyzed using ImageJ
by measuring the background subtracted mean fluorescence
intensity (MFI) of the cells, excluding the nucleus area, over
time.
2.8. Statistical Analysis. Datawere statistically analyzed using
GraphPad Prism. All data were reported as mean ± stan-
dard error of the mean (SEM). Differences between groups
were examined for statistical significance using a two-tailed
unpaired Student’s t-test (with Welch’s correction if neces-
sary), Fisher’s test or ANOVA. Significance of the differences
was indicated as follows: 𝑃 < 0.05: ∗ versus control, §
versus 10 ng/mL ActA, # versus 25 ng/mL ActA, and + versus
50 ng/mL ActA; 𝑃 < 0.01: ∗∗ versus control, §§ versus
10 ng/mL ActA, ## versus 25 ng/mL ActA, and ++ versus
50 ng/mL ActA; and 𝑃 < 0.001: ∗∗∗ versus control, §§§
versus 10 ng/mL ActA, ### versus 25 ng/mL ActA, and +++
versus 50 ng/mL ActA.
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3. Results
3.1. Activin A Dose-Dependent Regulation of Pluripotency and
Lineage Markers during Early Cardiomyocyte Differentiation.
The human ESC lines H1 and H9 were differentiated towards
CMs, according to the protocol described (see Materials
and Methods; Figures 1(a)–1(h)). During the early phase
of cardiac differentiation, human ESCs in EB aggregates
were treated with different concentrations of ActA, ranging
from 0 to 100 ng/mL. Addition of 10, 25, 50, or 100 ng/mL
ActA resulted in a more pronounced downregulation of
the pluripotency markers OCT4 and NANOG (Figure 2(a)).
To investigate the effect of ActA on the early cell fate
during in vitro cardiac differentiation, the expression of
genes corresponding to the three developmental lineages was
determined. Pretreatment with ActA did not increase the
expression of the mesodermal marker BRACH on day 2 of
differentiation, although a significant downregulation was
observed at day 4 in the presence of 100 ng/mL ActA com-
pared to the untreated condition (0 ng/mL ActA; Figure 2(b),
left panel). Moreover, the cardiac progenitor marker NKX2.5
was significantly upregulated on day 7 in human ESC-CMs
treated with 100 ng/mL ActA (Figure 2(b), right panel). As
expected, ActA treatment did not direct the differentiation
process towards the ectodermal lineage, although a transient
upregulation of PAX6 was observed in response to ActA
(Figure 2(c)). Interestingly, ActA significantly increased early
and intermediate endodermal markers, respectively, SOX17
(Figure 2(d), left panel) and HNF4𝛼 (Figure 2(d), right
panel). Thus, addition of ActA during the initial step of
differentiation induced a faster and stronger decrease in the
pluripotency and promoted a mesendodermal cell fate, sig-
nificantly shown by the expression of BRACH and SOX17. A
concentration of 100 ng/mLActAwas themost favourable for
efficient cardiac progenitor cell induction via mesendoderm.
3.2. Activin A Promoted Induction of Cardiomyocytes. To
investigatewhether a high dose ofActA could support further
differentiation into CMs, EB morphology of human ESC-
CMs at days 4, 5, 7, and 9 of differentiation was evaluated
after a treatment with 50 and 100 ng/mL ActA. At day 4, EBs
exhibited a comparable appearance irrespective of the ActA
concentrations applied (data not shown). At days 5, 7, and 9,
round shaped EBs were formed in the control condition and
when high concentrations of ActA (50 or 100 ng/mL) were
added to the mesoderm induction medium (Figure 3(a)). In
the control and high dose ActA conditions, EBs contained
a significant surface area of contracting CMs (Supplemental
Online Videos 1A and 1D-E, in Supplementary Material
available online at https://doi.org/10.1155/2017/4651238). No
significant additional proliferative effect of ActAwas detected
at day 2 of EB-based cardiac differentiation (Figure 3(b)).
The mean beating frequency of the EBs treated with 50 and
100 ng/mL ActA was, respectively, 54 (53.8 ± 2.49) and 66
(66.0±2.92) beats/min, while 48 (47.6±2.70) beats/min were
registered for the control (Figure 3(c)). Spontaneous beating
EBs were observed at day 10 of differentiation.The percentage
of contracting human ESC-CM EBs was 61% (60.8 ± 15.83)
for control conditions and increased to, respectively, 71%
(71.4 ± 12.36) and 88% (87.5 ± 11.34) for EBs treated with
50 and 100 ng/mL ActA, resulting in a remarkable increase
of contracting EBs (Figure 3(d)). To confirm the effect of
ActA on the CM differentiation efficiency, we analyzed the
gene expression profiles of the late-stage CMmarkersTNNT2
and cMyHC. On day 7 of differentiation, the expression of
TNNT2 and cMyHC was upregulated in EBs treated with
50 or 100 ng/mL ActA compared to the control condition
(Figure 3(e)). Thus, the in vitro CM differentiation was
more efficient with high doses of ActA (50 and 100 ng/mL),
resulting in higher early CMmaturation.
3.3. Activin A Increased HNF4𝛼+ Cell Population during
Cardiac Differentiation. In line with the previously described
HNF4𝛼 gene expression analyses during ActA-induced car-
diac differentiation (Figure 2(d), right panel), immunostain-
ing demonstrated that HNF4𝛼+ endoderm-like cells were
present and, moreover, in close proximity of the cMyHC+
CMs in 7-day-old EBs in control and 50 and 100 ng/mL ActA
treated conditions (Figure 4(a)). ActA promoted the differen-
tiation towards a HNF4𝛼+ endoderm-like cell population via
mesendoderm induction, as demonstrated by the quantifica-
tion of HNF4𝛼+ nuclei that increased to 18% (17.5±3.92) and
19% (19.0 ± 1.43) in, respectively, the 50 and 100 ng/mL ActA
treated conditions compared with 9% (9.2±2.15) reported in
the control (Figure 4(b)). ActA increased also the percentage
of cMyHC+ cells, 62% (61.6 ± 6.25) in the 50 ng/mL and 69%
(68.9 ± 6.80) in the 100 ng/mL ActA treated cells compared
to 49% (49.2 ± 14.05) in the control condition (Figure 4(b)).
Thus, addition of high concentrations of ActA increased
the percentage of cMyHC+ CMs, confirming an increased
HNF4𝛼+ endoderm-like cell generation mediated by ActA.
3.4. Antagonizing CRIPTO-1 Signaling Impaired Cardiomy-
ocyte Differentiation. To understand the influence of an
ActA addition on the expression of members of the TGF-𝛽
signaling pathway during our ESC EB-based cardiac differ-
entiation in a human setting, gene expression analyses were
performed for NODAL, CRIPTO-1, and the transmembrane
types I (ALK4 or ACVR1B) and II (ACVR2A and ACVR2B)
activin receptors. No significant differences were observed
in the expression levels of ALK4, ACVR2A, and ACVR2B in
response to the different ActA concentrations (Supporting
Information Fig. 1). However, the expression of NODAL
and CRIPTO-1 transcripts was significantly increased in an
ActA dose-dependent way at days 2 and 4 (no ActA dose-
dependent effect observed at day 7), suggesting that both
signaling molecules were closely related (Figure 5(a), left
and right panel). In undifferentiated human ESCs, CRIPTO-
1 gene expression has been shown to be high (Figure 5(a),
right panel, dashed line). During differentiation, CRIPTO-1
expression decreased significantly in the control condition
starting from day 2. Human ESCs treated with different
ActA concentrations showed a dose-dependent increase in
CRIPTO-1 levels observed on day 2 compared to controls.
When treatedwith 100 ng/mLActA,CRIPTO-1 transcripts on
day 2 were maintained at expression levels found in undif-
ferentiated human ESCs. From day 4 onwards, CRIPTO-1
content decreased drastically in all conditions (Figure 5(a),
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Figure 2: Gene expression analyses of human embryonic stem cells (ESCs) subjected to cardiac differentiation in the presence of Activin
A (ActA). Expression profiles of human ESC-derived CMs (ESC-CMs) for (a) pluripotency (OCT4, NANOG), (b) mesodermal (BRACH,
NKX2.5), (c) ectodermal (PAX6, SOX1), and (d) endodermal (SOX17, HNF4𝛼) lineage markers, monitored at days 0, 2, 4, and 7 of
differentiation. Dashed lines show basal expression levels of undifferentiated ESCs. Each data point is represented as ΔC𝑡, normalized for the
housekeeping genes GAPDH, HPRT, and RPL13a. Note that ActA treatment during the early phase of cardiomyocyte (CM) differentiation
directed human ESCs towards the mesendoderm cell fate. Data are representative of three independent experiments and values are expressed
as mean ± standard error of the mean (SEM). Significant differences are indicated as 𝑃 < 0.05: ∗ versus control, $ versus 10 ng/mL ActA, and
# versus 25 ng/mL ActA; 𝑃 < 0.01: ∗∗ versus control; 𝑃 < 0.001: ∗∗∗ versus control.
right panel). To confirm the importance of CRIPTO-1 during
cardiac differentiation, theCFC1/CRIPTO-1 blocking peptide
(CRIPTO-1 BP) was added from day 0 until day 2 of differ-
entiation in combination with 100 ng/mL ActA (Supporting
Information Fig. 2). Addition of CRIPTO-1 BP resulted in
a significantly decreased BRACH transcript level on day 2
(Figure 5(b)). Moreover, we observed impairment in the EB
structure in the presence of CRIPTO-1 BP (Figure 5(c) and
Supplemental Online Video 2A-B).The percentage of beating
EBs was evaluated on day 13. CRIPTO-1 BP significantly
reduced the percentage of beating EBs from 80% (79.9±2.60)
to 17% (17.3 ± 1.85) (Figure 5(d)). In addition, the surface of
the beating areas was decreased in the presence of CRIPTO-1
BP (83.9 ± 3.45 versus 8.1 ± 1.41) (Figure 5(e)). Thus, high
concentrations of ActA maintained high levels of CRIPTO-1
expression during the early phase of cardiac differentiation.
Blocking the CRIPTO-1 signaling pathway impaired cardiac
differentiation in vitro.
3.5. CRIPTO-1 Was Expressed by Activin A-Induced HNF4𝛼+
Endoderm-Like Cells. It has already been shown that Cripto-1
was highly present inmurinemesendoderm cells [32, 33] and
that it could promote CMdifferentiation [31, 34]. However, in
the human setting, the cell fraction that expressed CRIPTO-
1 was still unknown. We hypothesized that HNF4𝛼+ endo-
derm-like cells, induced by ActA, might express the mem-
brane-bound isoform of CRIPTO-1. As a consequence,
HNF4𝛼+ cells could be responsible for an improved CM dif-
ferentiation efficiency through a CRIPTO-1-mediated mech-
anism. By flow cytometric analyses, undifferentiated human
ESCs stained positive for CRIPTO-1 and negative for
HNF4𝛼 (Supporting Information Fig. 3A-B). The CRIPTO-
1+ HNF4𝛼+ cell population was quantified at day 3 of cardiac
differentiation with a percentage that varied in an ActA
concentration-dependent manner (Figure 6). In the control
condition, 9.52% (±1.58) of the differentiating cells were
double positive for CRIPTO-1 and HNF4𝛼 (first panel).
In the 10 and 25 ng/mL ActA condition, the number of
double positive cells is similar to controls (second and third
panel). However, the percentage of CRIPTO-1+HNF4𝛼+ cells
increased at high doses of ActA, respectively, 19.20% (±0.95)
for 50 ng/mL ActA and 22.00% (±3.25) for 100 ng/mL ActA
(fourth and fifth panel). These results were in consonance
with the immunostaining data for HNF4𝛼 quantification
(Figure 4(b)). These data demonstrated that a high dose of
50 and 100 ng/mL ActA increased the percentage of HNF4𝛼+
endoderm-like cell population expressing the surface-bound
fraction of CRIPTO-1.
3.6. Activin A Treatment during Early Cardiac Differentiation
Supported Maturation towards Cardiomyocytes. For the car-
diac differentiation, we used 25 ng/mL BMP4 and 5 ng/mL
bFGF to initiate mesoderm induction. To induce NKX2.5+
cardiac progenitor cells, the IWR-1 Wnt signaling pathway
inhibitor was added on day 4 (Supporting Information Fig.
4A-C). IWR-1 has been shown to direct human ESC-CM
differentiation towards an atrial-like phenotype [41]. To study
the CM subtype specification in response to ActA, APs of
dissociated EB-CMs were analyzed at day 25 of differenti-
ation using the patch clamp technique (Figures 7(a)–7(c)).
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Figure 3: ActA increased human ESC-CM differentiation efficiency. High doses of 50 and 100 ng/mL ActA promoted CM differentiation.
(a) Brightfield images of EB morphology at days 5, 7, and 9 of differentiation of ActA treatment conditions (50 and 100 ng/mL) compared
to the untreated cells (0 ng/mL ActA). (b) Proliferation was assessed using Ki-67, showing that 6.95% of the control cells and 8.94% of the
ActA treated cells were in a proliferative stage. Flow cytometry analysis is a representative example of three independent experiments. (c)
Quantification of contracting rate (beating frequency EBs per minute) and (d) percentage of contracting EBs at day 10 of differentiation.
Efficiency is expressed as percentage of wells containing beating EBs to the total number of wells. (e) Gene expression analyses of late-stage
CM genes (TNNT2, cMyHC) during 13 days of differentiation. Dashed lines show basal expression levels of undifferentiated ESCs. Each data
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Figure 4: ActA promoted CM differentiation by inducing HNF4𝛼+ endoderm-like cell population. High doses of 50 and 100 ng/mL ActA
during the early phases of cardiac differentiation increased the amount of HNF4𝛼+ endoderm-like cells, which subsequently promoted the
CM differentiation efficiency. (a) IF analyses for HNF4𝛼 (green), cMyHC (red), and Hoechst (blue) in 7-day-old EBs for control and 50 and
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(b) Quantifications of cMyHC+, HNF4𝛼+ and cMyHC− HNF4𝛼− cell populations in the presence (50 and 100 ng/mL) or absence of ActA
are reported as percentages of control conditions. Data are representative of three independent experiments and expressed as mean ± SEM.
Significant differences are versus control and indicated as 𝑃 < 0.05: ∗; 𝑃 < 0.01: ∗∗; and 𝑃 < 0.001: ∗∗∗. Scale bar = 100 𝜇m.
Firstly, we measured the resting membrane potential (RMP)
(Figure 7(a)). Cells treated with ActA (𝑛 = 11) were well
polarized with a RMP of −70mV or more negative, whereas
the RMP for cells without ActA (𝑛 = 17) showed a more
heterogeneous distribution. These data suggested a lower
degree of maturation without ActA. To study AP character-
istics, cells with a low RMP (i.e., more positive than −40mV,
𝑛 = 2) were excluded. Then, the APD30 and APD50 (30%
and 50% repolarization) for early repolarization properties
of the APs were measured (Figure 7(b), right and left panel).
In the absence of ActA, early repolarization (low APD30)
appeared to be common (11/15 cells had an APD30 lower
than 15ms versus 4/11 cells with ActA). Moreover, this could
also be observed for APD50 where 8 cells had an APD50
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Figure 5: Human ESC-CM differentiation potential after CRIPTO-1 interference. CRIPTO-1 blocking peptide (BP) impaired ActA-directed
in vitro cardiac differentiation. (a) Gene expression of the TGF-𝛽 family members NODAL and CRIPTO-1 during a 13-day differentiation
period. Dashed lines show basal expression levels of undifferentiated ESCs. (b) Normalized fold change of the mesodermal marker BRACH,
measured at day 2 of differentiation after CRIPTO-1 BP treatment. Data, normalized for the housekeeping genes GAPDH, HPRT, and
RPL13a, are representative of three independent experiments and expressed as mean ± SEM. (c) Brightfield pictures of ESC-CMs at day
13 of differentiation after CRIPTO-1 BP treatment or after addition of a human CRIPTO-1 antibody (Ab). (d) Percentage of contracting EBs
and of (e) beating area surface in differentiated CMs pretreated with 100 ng/mL ActA and 5 𝜇MCRIPTO-1 BP or pretreated with 100 ng/mL
ActA and a human CRIPTO-1 Ab (10 𝜇M). Data, normalized for the housekeeping genes GAPDH, HPRT, and RPL13a, are representative of
four independent experiments and expressed as mean ± SEM. Significant differences are indicated as 𝑃 < 0.05: ∗ versus control; 𝑃 < 0.01:
∗∗ versus control and §§ versus 10 ng/mL ActA; 𝑃 < 0.001: ∗∗∗ versus control. Scale bar = 200 𝜇m.
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lower than 30ms without ActA and none was with ActA.
This indicated that there was a trend that cells had a more
pronounced plateau phase in the presence ofActA.According
to the overall profile and the previously measured properties
(APD30, APD50), we categorized the cells into an atrial-like
or a ventricular-like phenotype (Figures 7(c)–7(d)), without
ActA 9/15 cells had an atrial-like profile versus 4/11 cells with
ActA (Fisher’s test = NS). However, it is important to note
that there was a spectrum of APs from an atrial-like to a
ventricular-like phenotype, as recently described in human
iPSC-CMs [42]. After 40 days in culture, we could also
observe cytosolic Ca2+ transients accompanying the stimu-
lated APs (Figure 6(e) and Supplemental Online Video 3).
Taking these data together, the protocol used here for cardiac
differentiation (with and without 100 ng/mL ActA) allowed
production of atrial- and ventricular-like CMs associated
with AP and Ca2+ transients, showing a trend for a more
homogeneous phenotype and polarization with ActA.
4. Discussion
Human ESCs exhibit the potential to generate functional
cell types that can be used as renewable cell source to study
embryogenesis and, consequently, gain better insights in
signaling pathways involved in PSC-driven differentiation,
including lineage specification, lineage commitment, and
terminal differentiation.
In the current study we analyzed the role of ActA on the
early formation of primitive streak andmesoderm/endoderm
fromhuman ESCs during cardiac differentiation.We demon-
strated, in the here described cardiac differentiation pro-
tocol, high concentrations of ActA during the initial steps
of differentiation fated human ESCs towards CMs with a
prevalent ventricular-like AP phenotype and with AP and
Ca2+ handling properties similar tomature cardiacmyocytes.
To study the intercellular interactions between mesoder-
mal and endodermal cell populations, an EB-based car-
diac differentiation system was applied, representing better
the three-dimensional (3D) environment of human cardiac
development. A clinicallymore relevant EB-based serum-free
protocol has been described as alternative for our protocol,
though less efficient and therefore less suitable for mesoder-
mal/endodermal interaction studies [38]. For translational
purposes, a monolayer in serum-free conditions would be
the most pertinent protocol to generate human ESC-derived
ventricular CMs to develop a platform for pharmacological
screening or to study heart diseases.
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Figure 7: Phenotyping CM differentiation showed both atrial- and ventricular-like (action potentials) APs. (a) Resting membrane potential
(RMP) of humanESCs-CMs,measured during current clamp (whole-cell patch clamp recording)with orwithout a pretreatment of 100 ng/mL
ActA. Each data point is a single cell measurement. (b) AP duration at 30% and 50% repolarization (APD30 and APD50). (c) Example of
AP from a typical ventricular-like cell (left panel) and an atrial-like cell (right panel). (d) Percentages of CMs exhibiting an atrial-like or
ventricular-like AP phenotype with and without ActA addition. (e) Simultaneous intracellular Ca2+ measurements using Fluo-4 and current
clamp recording in a human ESC differentiated into CMs.
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Several studies have been conducted to explore the inter-
play between the TGF-𝛽/ActA/NODAL, bFGF, and BMP
signaling pathways on early cell fate determination. However,
conflicting results exist regarding the effects of these pathways
in mouse and human ESCs. Addition of ActA alone has
been shown to maintain self-renewal properties [43] and
ActA/NODAL together with bFGF signaling coordinately
maintained pluripotency in human ESCs [44]. Studies in
mouse ESCs indicated that either BMP4 or ActA alone or
in combination induced primitive streak markers, even if
BMP4 seemed to exert a dominant effect [45, 46]. Recently,
Fiorenzano et al. have reported an early function of CRIPTO-
1 in the very first lineage decision made by the early embryo.
CRIPTO-1 was one of the earliest epiblast markers and played
a pivotal functional role in the acquisition and maintenance
of mouse and human pluripotency. Moreover, they demon-
strated that CRIPTO-1 was required to generate and sustain
bFGF/ActA EpiSCs, and a CRIPTO-1 deficiency skewed
ESC differentiation towards the trophoblast lineage in vitro
[35].
Inhibition of ActA signaling blocked mesendoderm
induction in BMP4 treated mouse ESCs, while BMP4 sig-
naling inhibition had no impact on the mesendodermal cell
fraction observed in in vitro cultures treated with ActA,
thereby pointing out the pivotal role of ActA/Nodal signaling
in mesendoderm formation. Moreover, ActA induced higher
levels of the anteriormesendoderm/early endodermmarkers,
Foxa2 and Sox17, while BMP4 slightly upregulated these
genes [46]. Similarly, mouse ESCs treated with high levels of
ActA differentiated in a more anterior streak fate, including
cardiac mesoderm and definitive endoderm [14]. For human
PSCs, there was evidence that a short-term BMP4 treat-
ment of human ESCs promoted mesoderm differentiation
[47]. There was also evidence that although ActA signaling
was permissive for differentiation of human ESCs towards
mesendodermal cell fate, it was not sufficient. However,
human PSC differentiation to mesoderm, and subsequently
CMs, was more robust when a combination of BMP4/ActA
[21] or a combination of BMP4, bFGF, and ActA was used
[20]. Interestingly, one study reported that differentiation
of human ESCs with BMP4 but without ActA resulted
in a decreased survival rate and decreased efficiency in
generating mesendoderm and/or mesoderm [47]. Consistent
with these studies, we demonstrated that the addition of
ActA in combination with BMP4 and bFGF increased the
expression of the early endodermal marker SOX17 and the
definitive endodermal markerHNF4𝛼 in human ESCs. More
recently, a monolayer-based cardiac differentiation protocol
has been published, applying theWnt signaling agonist CHIR
in combination with high or low levels of ActA [48]. This
study is not in contrast with our data. In fact, consistent
with our results the authors showed that coinduction with
CHIR and high ActA levels induced definitive endoderm,
whereas CHIR supplemented with low ActA levels improved
cardiomyogenic efficiency. By contrast, CHIR plus low levels
of BMP4 consistently and strongly inhibited cardiomyoge-
nesis. With our work, we extended this study and provided
novel mechanistic insights. We identified an upregulation of
the endodermal genes SOX17 and HNF4𝛼 associated with
increased CRIPTO-1 signaling when ActA was added during
early CM differentiation.
The ActA/NODAL/CRIPTO-1 signaling plays an impor-
tant role in maintaining human ESCs in an undifferenti-
ated pluripotency state [49, 50]. Several previously pub-
lished papers have indicated Cripto-1 as a critical player in
mouse cardiomyogenesis. Similarly to our CRIPTO-1 block-
ing experiments, Cripto-1 knockout mouse ESCs lacked the
ability to generate beating CMs in vitro [31]. Minchiotti et al.
demonstrated that the Nodal/Cripto-1 pathway was involved
in mouse ESC differentiation towards functional beating
CMs,while preventing neuroectodermdifferentiation [33, 50,
51]. Moreover, mesendodermal cells highly expressed Cripto-
1 [32, 33]. The dynamics of Cripto-1 signaling, including
timing, strength, and duration of the signal, have been des
cribed to be critical for correct specification and differenti-
ation of the cardiac lineage. Cripto-1 signaling needed to be
initiated in an early acting window of time, and the transient
presence of Cripto-1 was inadequate, while sustained Cripto-
1 signaling (at least 24 hours) was required to promote card
iomyogenesis [33]. Another study reported that hypoxia-
mediated murine ESC differentiation to mesendoderm for-
mation, and subsequently CM differentiation, occurred via
a Cripto-1-mediated signaling pathway [34]. However, none
of these studies succeeded in defining a human origin for
CRIPTO-1 expression. In our study, we confirmed that the
addition of ActA, in a dose-dependent manner, increased
CRIPTO-1 transcripts in the mixed EB progeny. We showed
for the first time that, in anEB-based differentiation of human
ESC towards CMs, CRIPTO-1 induction was required to
induce differentiation towards CMs. As CRIPTO-1 existed
either as a cell membrane or as secreted isoform, precise
examination of the cell types expressing CRIPTO-1 was diffi
cult.We observed that the addition of ActA resulted in a signi
ficantly greater population of HNF4𝛼+ endodermal cells in
the EB outgrowth. Our data has shown that, within ActA
exposed EBs, the HNF4𝛼+ endoderm-like cell population
expressed CRIPTO-1 and that CRIPTO-1 expression in the
HNF4𝛼+ cells was maintained at levels found in undifferen-
tiated human ESC at day 2 of differentiation. Therefore, we
suggested thatHNF4𝛼+ cells could be important contributors
of the increased human CM differentiation via a CRIPTO-1
signaling mechanism.
Consistent with our results, Mummery et al. have already
identified visceral endoderm cells as a source of molecular
cues that resulted in human ESCs differentiating to CMs [4].
Further studies will be useful to understand if HNF4𝛼+ cells
were the original visceral endoderm inducers to promote CM
differentiation and eventuallymaturation in order to build up
robust CM differentiation protocols from human ESCs.
The inclusion of high levels of insulin during the early
stage of cardiac differentiation has been shown to induce
strong inhibitory effects on cardiomyogenesis [52]. Indeed,
in a more recent paper, insulin has been shown to inhibit
cardiac mesoderm, but not mesendoderm formation, during
cardiac differentiation induced by using TGF-𝛽 superfamily
ligands. However, the authors claimed that the modulation of
the canonical Wnt signaling pathway can rescue this insulin-
mediated inhibition [53]. We confirmed the release of the
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insulin inhibitory effect by adding the Wnt inhibitor IWR-1
during the cardiac progenitor stage.
Human PSC-CMs offer a potentially relevant model
system for drug discovery. Despite their suitability for car-
diotoxicity testing and safety pharmacology, their application
in validating novel drug candidates for atrial- or ventricular-
specific heart disorders requires in vitro cultures enriched in
atrial- or ventricular-like CMs. Currently, cardiac differenti-
ation protocols of human PSCs result usually in a heteroge-
neous pool of atrial-, ventricular-, and nodal-like CMs [3].
A recently published paper has reported the importance of
the exogenous addition of retinoic acid (RA) during human
ESC differentiation for atrial chamber cell development [54].
Treating differentiating human ESCs with theWnt inhibitors,
IWP-4 and IWR-1, resulted in CMs with differing atrial and
ventricular expression levels of, respectively, MLC-2a and
MLC-2v [55]. Inhibition of the Wnt signaling pathway by
using IWR-1 has been shown to differentiate human ESC-
CMs towards mostly atrial-like CMs [41]. However, conflict-
ing data exist [56]. Human ESCs, subjected to the protocol
described in this study with ActA, were well polarized and
with a trend towards a predominant ventricular AP pheno-
type. Further studies will examine the persistence and further
development of this phenotype at later time points. Interest-
ingly, cells treated with ActA exhibited a RMP of −70mV or
more negative, whereas the RMP for cells without ActA treat-
ment showed a more heterogeneous distribution, suggesting
a lower degree of CMmaturation in the absence of ActA.
In conclusion, high concentrations of ActA during the
initial phase of EB-based cardiac differentiation enhanced the
definitive endodermal cell population, which in turn pro-
moted differentiation of human ESCs towards CMs, and
maturation in early stages of differentiation, improving the
beating frequency and the percentage of contracting EBs.
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